Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02989636
Other study ID # J16138
Secondary ID IRB00117650NCI-2
Status Active, not recruiting
Phase Phase 1
First received
Last updated
Start date March 10, 2017
Est. completion date November 2026

Study information

Verified date June 2024
Source Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase I trial studies the side effects of nivolumab with or without stereotactic radiosurgery (SRS) in treating patients with chordoma that has come back or spread from where it started to other places in the body. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. It is not yet known whether giving nivolumab with or without stereotactic radiosurgery may work better in treating patients with chordoma.


Description:

PRIMARY OBJECTIVES: I. To assess the safety profile of nivolumab alone and nivolumab in combination with stereotactic radiosurgery to treat patients with recurrent or advanced chordoma. SECONDARY OBJECTIVES: I. To evaluate toxicity and tolerability of nivolumab alone and nivolumab in combination with stereotactic radiosurgery. II. To estimate growth modulation index on target lesion. III. To estimate a clinical response (partial response [PR] + complete response [CR] within 6 month + stable disease [SD] beyond 6 months). IV. To assess progression-free survival and progression-free survival (PFS) rate at 6 months. V. To assess overall survival rate at 1 year, 3 years and 5 years. TERTIARY OBJECTIVES: I. To explore peripheral blood immune response during and after treatment. OUTLINE: Patients are assigned to 1 of 2 arms. ARM I: Patients receive nivolumab intravenously (IV) over 30 minutes on day 1. Courses repeat every 14 days for 2 years in the absence of disease progression or unacceptable toxicity. ARM II: Patients receive nivolumab as in Arm I. Patients undergo stereotactic radiosurgery (SRS) as per standard of care on day 8 of course 1. After completion of study treatment, patients are followed up at 100 days and every 10 weeks thereafter.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 21
Est. completion date November 2026
Est. primary completion date April 24, 2024
Accepts healthy volunteers No
Gender All
Age group 15 Years and older
Eligibility Inclusion Criteria: - Patients must have histologically confirmed diagnosis of chordoma; the pathologic confirmation may be from another metastatic site - Patients may have metastases, with newly identified peripheral metastases - Cross-sectional imaging evidence of progression of recurrent or metastatic disease - Previous treatment information (name of agent, treatment starting date, and date of progression) must be available for review - Measurable disease in one or more site. (Per RECIST criteria: Measurable lesions are defined as those that can be accurately measured in at least one dimension (longest diameter to be recorded) as >= 10 mm with CT scan, MRI, or calipers by clinical exam. All tumor measurements must be recorded in millimeters (or decimal fractions of centimeters)). - Karnofsky performance scale >= 70% - White blood cells (WBC) >= 3,000/mcL - Absolute neutrophil count >= 1,500/mcL - Platelets >= 100,000/mcL - Total bilirubin =< 2 x institutional upper limit of normal - Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x institutional upper limit of normal - Creatinine within normal institutional limits OR according to Johns Hopkins magnetic resonance imaging (MRI) policy - Women of child bearing potential (WOCBP) should use an adequate method to avoid pregnancy for 5 months plus the time required for nivolumab to undergo approximately five half-lives) after the last dose of investigational drug; in order for a woman to be determined not of child-bearing potential, she must have >= 12 months of non-therapy induced amenorrhea or be surgically sterile - Men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 7 months after the last dose of investigational product - Ability to understand and the willingness to sign written informed consent document(s) Exclusion Criteria: - Prior chemotherapy within 21 days or 5 half-lives (whichever is shorter) days of starting treatment - Prior therapy with investigational drugs within 21 days or at least 5 half-lives (whichever is shorter) before study administration - Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PDL-2 antibody - Neurologic dysfunction that would confound the evaluation of neurologic and other adverse events - Known allergy to compounds of similar chemical or biologic composition to nivolumab - Pregnant or breastfeeding women - Known history of human immunodeficiency virus - Active infection requiring therapy, including positive tests for hepatitis B surface antigen or hepatitis C ribonucleic acid (RNA) - Active autoimmune disease, history of autoimmune disease or history of syndrome that required systemic steroids or immunosuppressive medications, e.g. organ, tissue, or allogenic hematopoietic stem cell transplant (HSCT) recipients. Exceptions include those with resolved childhood asthma/atopy. Subjects with asthma who require intermittent use of bronchodilators (such as albuterol) will not be excluded from this study. Subjects are also permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger - Patients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease - Use of any vaccines against infectious diseases (e.g. varicella, influenza, etc.) up to 4 weeks (28 days) before receiving nivolumab - Prisoners or subjects who are compulsorily detained for treatment of either a psychiatric or physical (e.g. infectious disease) illness - Prior radiation doses equivalent to, or greater than, 8000 cGy in 200 cGy fractions - Any radiation to the target lesions within 6 months of enrollment - Unable to meet radiation treatment plan parameters - Unavailable for follow up visits after treatment - Prior malignancy unless disease free for = 2 years. Curatively treated basal or squamous cell carcinoma of the skin, totally excised melanoma of stage IIA or lower, low- or intermediate-grade localized prostate cancer (Gleason sum =7), and curatively-treated carcinoma in situ of the cervix, breast, or bladder are allowed regardless.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Laboratory Biomarker Analysis
Correlative studies
Biological:
Nivolumab
Given IV
Radiation:
Stereotactic Radiosurgery
Undergo SRS

Locations

Country Name City State
United States Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore Maryland
United States Memorial Sloan-Kettering Cancer Center New York New York

Sponsors (4)

Lead Sponsor Collaborator
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Bristol-Myers Squibb, Chordoma Foundation, National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of dose limiting toxicities evaluated according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 Proportion of serious adverse events will be estimated using the binomial distribution along with 95% confidence interval (exact method). Up to 12 weeks after initial dose of nivolumab
See also
  Status Clinical Trial Phase
Completed NCT03955042 - Pemetrexed for the Treatment of Chordoma Phase 1
Completed NCT01347307 - Stereotactic Body Radiotherapy for Spine Tumors N/A
Active, not recruiting NCT00496119 - Proton Beam Therapy for Chordoma Patients Phase 2
Recruiting NCT06029218 - Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy N/A
Completed NCT03595228 - BN Brachyury and Radiation in Chordoma Phase 2
Recruiting NCT06140732 - Apatinib Combined With Camrelizumab in Treating Participants With Advanced Chordoma Phase 2
Active, not recruiting NCT01175109 - Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma Phase 1
Completed NCT00150072 - Efficacy and Safety of Imatinib in Chordoma Phase 2
Terminated NCT00003926 - Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors Phase 1
Recruiting NCT05041127 - Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma Phase 2
Recruiting NCT05861245 - Hypofractionated Protontherapy in Chordomas and Chondrosarcomas of the Skull Base N/A
Completed NCT00464620 - Trial of Dasatinib in Advanced Sarcomas Phase 2
Completed NCT02383498 - QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma Phase 2
Recruiting NCT03242382 - Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression. Phase 2
Completed NCT02520128 - A Study of IMRT in Primary Bone and Soft Tissue Sarcoma N/A
Recruiting NCT01567046 - Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas N/A
Recruiting NCT02986516 - Sacral Chordoma: Surgery Versus Definitive Radiation Therapy in Primary Localized Disease N/A
Completed NCT00919269 - Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma
Active, not recruiting NCT03083678 - Afatinib in Locally Advanced and Metastatic Chordoma Phase 2
Completed NCT00713037 - Hypoxia-positron Emission Tomography (PET) and Intensity Modulated Proton Therapy (IMPT) Dose Painting in Patients With Chordomas N/A